Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy

Antiviral Research

Volumn 55, Issue 3, 2002, Pages 397-412

  Borowski, Peter ^a   Schalinski, Sarah ^a   Schmitz, Herbert ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

Flaviviridae; Hepatitis C virus; Nucleoside triphosphatase helicase; Target for antiviral therapy

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIVIRUS AGENT; DAUNORUBICIN; DOUBLE STRANDED RNA; DOXORUBICIN; ENZYME INHIBITOR; EPIRUBICIN; HELICASE; HETEROCYCLIC AMINE; MITOXANTRONE; NOGALAMYCIN; NUCLEOSIDE TRIPHOSPHATASE; NUCLEOSIDE TRIPHOSPHATE; NUCLEOTIDE; PACLITAXEL; PIPERIDINE DERIVATIVE; POLYNUCLEOTIDE; RIBAVIRIN DERIVATIVE; RIBAVIRIN DIPHOSPHATE; RIBAVIRIN TRIPHOSPHATE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ALLOSTERISM; COMPETITIVE INHIBITION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME SUBSTRATE; FLAVIVIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYDROGEN BOND; HYDROLYSIS; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN TRANSPORT; REVIEW; RNA BINDING; RNA STRUCTURE; STEREOSPECIFICITY; VIRUS GENOME;

ACID ANHYDRIDE HYDROLASES; ANTIVIRAL AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HEPACIVIRUS; NUCLEOSIDE-TRIPHOSPHATASE; VIRAL NONSTRUCTURAL PROTEINS;

FLAVIVIRIDAE; HEPATITIS C VIRUS;

EID: 0036752091     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00096-7     Document Type: Review

References (85)

1. Bachur N., Yu F., Johnson R., Hickey R., Wu Y., Malkis L. Helicase inhibition by anthracycline anticancer agents. Mol. Pharmacol. 41:1992;993-998.
2. Balzarini J., Karlson A., Wang L., Bohman C., Horska K., Votruba I., Fridland A., Van Aerschot A., Herdewijn P., De Clerq E. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J. Biol. Chem. 268:1993;24591-24598.
3. Banerjee R., Dasgupta A. Specific interaction of hepatitis C virus protease/helicase NS3 with the 3′-terminal sequences of viral positive- and negative-strand RNA. J. Virol. 75:2001;1708-1721.
4. Bartenschlager R. Candidate targets for hepatitis C virus-specific antiviral therapy. Intervirology. 40:1997;378-393.
5. Blight K.J., Rice C.M. Secondary structure determination of the conserved 98-base sequence at the 3′ terminus of hepatitis C virus genome RNA. J. Virol. 71:1997;7345-7352.
6. Boehmer P.E., Lehman I.R. Herpes simplex virus type 1 ICP8: helix-destabilizing properties. J. Virol. 67:1993;711-715.
7. Borowski P., Heiland M., Oehlmann K., Becker B., Kornetzky L., Feucht H.-H., Laufs R. Non-structural protein 3 of hepatitis C virus inhibits phosphorylation mediated by cAMP-dependent protein kinase. Eur. J. Biochem. 237:1996;611-618.
8. Borowski P., Heiland M., Feucht H.-H., Laufs R. Characterization of non-structural protein 3 of hepatitis C virus as modulator of protein phosphorylation mediated by PKA and PKC; evidences for action on the level of substrate and enzyme. Arch. Virol. 144:1999a;687-701.
9. Borowski P., Kühl R., Mueller O., Hwang L.-H., Schulze zur Wiesch J., Schmitz H. Biochemical properties of a minimal functional domain with ATP- binding activity of the NTPase/helicase of hepatitis C virus. Eur. J. Biochem. 266:1999b;715-723.
10. Borowski P., Kühl R., Laufs R., Schulze zur Wiesch J., Heiland M. Identification and characterization of a histone binding site of the non-structural protein 3 of hepatitis C virus. J. Clin. Virol. 13:1999c;61-69.
11. Borowski P., Mueller O., Niebuhr A., Kalitzky M., Hwang L.-H., Schmitz H., Siwecka M.A., Kulikowski T. ATP-binding domain of NTPase/helicase as target for hepatitis C antiviral therapy. Acta Biochim. Polon. 47:2000;173-180.
12. Borowski P., Niebuhr A., Mueller O., Bretner M., Felczak K., Kulikowski T., Schmitz H. Purification and characterization of West Nile virus nucleoside triphosphatase (NTPase)/helicase: evidence for dissociation of the NTPase and helicase activities of the enzyme. J. Virol. 75:2001a;3220-3229.
13. Borowski P., Lang M., Niebuhr A., Haag A., Schmitz H., Schulze zur Wiesch J., Choe J., Siwecka M.A., Kulikowski T. Inhibition of the helicase activity of HCV NTPase/helicase by 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide-5′ triphosphate (ribavirin-TP). Acta Biochim. Polon. 48:2001b;739-744.
14. Borowski P., Lang M., Haag A., Schmitz H., Choe J., Chen H.-M., Hosmane R.S. Characterization of imidazo[4,5-d]pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: evidence for activity on the level of substrate and/or enzyme. Antimicrob. Agents Chemother. 46:2002;1231-1239.
15. Chase J.W., Wiliams K.R. Single-stranded DNA binding proteins required for DNA replication. Ann. Rev. Biochem. 55:1986;103-136.
16. Chen H.-M., Hosmane R.S. Synthesis of 1-(2′-O-methyl-β-D-ribofuranosyl)-1h-imidazo[4,5-d]pyridazine-4,7 (5h,6h)-dione: an attractive building block for antisense and triple-helical applications. Molecules. 6:2001;203-207.
17. Cho H.S., Ha N.C., Kang L.W., Chung K.M., Back S.M., Jang S.K., Oh B.H. Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA. J. Biol. Chem. 273:1998;15045-15052.
18. Choo L., Kuo G., Weiner A., Bradley D., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis. Science. 244:1989;359-362.
19. Choo L., Weiner A., Overby L., Kuo G., Houghton M. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br. Med. Bull. 46:1990;423-441.
20. Crute J.J., Grygon C.A., Hargrave K.D., Simoneau B., Faucher A.M., Bolger G., Kibler P., Liuzzi M., Cordingley M.G. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 8:2002;386-391.
21. De Clerq E., Cools M., Balzarini J., Snoieck R., Andrei G., Hosoya M., Shigeta S., Ueda T., Minakawa N., Matsuda A. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35:1991;679-684.
22. Deluca M.R., Kerwin S.M. The para-toluenosulfonic acid promoted synthesis of 2-substituted benzoxazoles and benzimidazoles from diacylated precursors. Tetrahedron. 53:1996;457-464.
23. Diana, G.D., Bailey, T.R., Nitz, T.J., 1998. Compounds, composition and methods for treatment of hepatitis C. U.S. Patent No. 6, 127 384.
24. Diana, G.D., Bailey, T.R., 1996. Compounds, composition and methods for treatment of hepatitis C. U.S. Patent No. 5, 633 388.
25. van Doorn J. Molecular biology of the hepatitis C virus. J. Med. Virol. 43:1994;345-356.
26. Fuller-Pace F.V. RNA helicases: modulators of RNA structure. Trends Cell Biol. 4:1994;271-274.
27. Gallinari P., Brennan D., Nardi C., Brunetti M., Tomei L., Steinkühler C., De Francesco R. Multiple enzymatic activities associated with recombinant NS3 of hepatitis C virus. J. Virol. 72:1998;6758-6769.
28. Ganapathi R., Kamath N., Constantinou A., Grabowski D., Ford J., Anderson A. Effect of the calmodulin inhibitor trifluoperazine on phosphorylation of P-glycoprotein and topoisomerase II: relationship to modulation of subcellular distribution, DNA damage and cytotoxicity of doxorubicin in multidrug resistant L1210 mouse leukemia cells. Biochem. Pharmacol. 41:1991;21-26.
29. Georgaki A., Strack B., Podust V., Hubscher U. DNA unwinding activity of replication protein A. FEBS Lett. 308:1992;240-245.
30. Gilbert B.E., Wilson Z.S., Knight V., Couch R.B., Quarles J.M., Dure L., Hayes N., Willis G. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob. Agents Chemother. 27:1985;309-313.
31. Gorbalenya A.E., Koonin E.V., Donschenko A.P., Blinov V.M. Two related superfamilies of putative helicases involved in replication, recombination, repair and expression of DNA and RNA genomes. Nucleic Acids Res. 17:1989;4713-4730.
32. Gorbalenya A.E., Koonin E.V. Viral proteins containing the purine NTP-binding sequence pattern. Nucleic Acids Res. 17:1989;8413-8440.
33. Gorbalenya A.E., Koonin E.V. Helicases: amino acid sequence comparisons and structure-function relationships. Curr. Opin. Struct. Biol. 3:1993;419-429.
34. Gordon F.D., Poterucha J.J., Germer J., Zein N.N., Batts K.P., Gross J.B. Jr., Wiesner R., Persing D. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after live transplantation. Transplantation. 63:1997;1419-1423.
35. Gu B., Liu C., Lin-Goerke J., Malley D.R., Gutshall L.L., Feltenberger C.A., Del Vecchio A.M. The RNA helicase and nucleotide triphosphatase activities of the bovine viral diarrhea virus NS3 protein are essential for viral replication. J. Virol. 74:2000;1794-1800.
36. Gwack Y., Kim D.W., Han J.H., Choe J. Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein. Biochem. Biophys. Res. Commun. 255:1996;654-659.
37. Hay B., Jan L.Y., Jan Y.N. A protein component of Drosophila polar granules is encoded by vasa and has extensive sequence similarity to ATP-dependent helicases. Cell. 55:1988;577-587.
38. Hesson T., Mannarino M., Cable A. Probing the relationship between RNA-stimulated ATPase and helicase activities of HCV NS3 using 2′-O-methyl RNA substrates. Biochemistry. 39:2000;2619-2625.
39. Huggins J.W., Kim G.R., Brand O.M., McKee T.K. Ribavirin therapy for Hantaan virus infection in suckling mice. J. Infect. Dis. 153:1986;489-497.
40. Ito T., Tahara S.M., Lai M.M. The 3′-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. J. Virol. 72:1998;8789-8796.
41. Kadare G., Haenni A. Virus-encoded RNA helicases. J. Virol. 71:1997;2583-2590.
42. Kim D.W., Gwack Y., Han J.H., Choe J. Towards defining a minimal functional domain for NTPase and RNA helicase activities of the hepatitis C virus NS3 protein. Virus Res. 49:1997;17-25.
43. Kim J.L., Morgenstern K., Griffith J., Dwyer M., Thomson J., Murcko M., Lin C., Caron P. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure. 6:1998;89-100.
44. Kumar P.K., Machida K., Urvil P.T., Kakiuchi N., Vishnuvardhan D., Shimotohno K., Taita K., Nishikawa S. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology. 237:1997;270-282.
45. Lain S., Riechmann L., Martin M.T., Garcia J.A. Homologous potyvirus and flavivirus proteins belonging to a superfamily of helicase-like proteins. Gene. 82:1989;357-362.
46. Lain S., Martin M.T., Riechmann J.L., Garcia J.A. Novel catalytic activity associated with positive-strand RNA virus infection: nucleic acid-stimulated ATPase activity of the plum pox potyvirus helicase-like protein. J. Virol. 65:1991;1-6.
47. Lee J.H., von Wagner M., Roth W.K., Teuber G., Sarrazin C., Zeucem S. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J. Hepatol. 29:1998;29-35.
48. Levin M.K., Patel S.S. The helicase from hepatitis C virus is active as an oligomer. J. Biol. Chem. 274:1999;31839-31846.
49. Lown J.W., Hanstock C.C., Bradley R.D., Scraba D. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy. Mol. Pharmacol. 25:1984;178-184.
50. Lüking A., Stahl U., Schmidt U. The protein family of RNA helicases. Crit. Rev. Biochem. Mol. Biol. 33:1998;259-296.
51. Lun L., Sun P.-M., Trubey C., Bachur N. Antihelicase action of CI-958, a new drug for prostate cancer. Cancer Chemother. Pharmacol. 42:1998;447-453.
52. Matson S.W., Kaiser-Rogers K.A. DNA helicases. Ann. Rev. Biochem. 59:1990;289-329.
53. Matusan A.E., Pryor M.J., Davidson A.D., Wright P.J. Mutagenesis of the dengue virus type 2 NS3 protein within and outside helicase motifs: effects on enzyme activity and virus replication. J. Virol. 75:2001;9633-9643.
54. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., Williams B. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314:1986;20-26.
55. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1998;1485-1492.
56. Miller H., Purcell R. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc. Natl. Acad. Sci. USA. 87:1990;2057-2061.
57. Mizokami M., Orito E. Molecular evolution of hepatitis viruses. Intervirology. 42:1999;159-165.
58. Monath T.P., Heinz F.X. Flaviviruses. Knipe D.M., Howley P.M., third ed. Fields Virology. 1:1996;961-1034 Lippincott-Raven Publishers, Philadelphia, PA.
59. Morgenstern K.A., Landro J.A., Hsiao K., Lin C., Young G., Su M.-S., Thomson J.A. Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of hepatitis C virus NS3-NS4A complex. J. Virol. 71:1997;3767-3775.
60. Neyts J., Meerbach A., McKenna P., De Clerq E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res. 30:1996;125-132.
61. Pallaoro M., Lahm A., Biasiol G., Brunetti M., Nardella C., Orsatti L., Bonelli F., Orru S., Narjes F., Steinkuhler C. Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. J. Virol. 75:2001;9939-9946.
62. Phoon C.W., Ng Y.P., Ting A.E., Yeo S.L., Sim M.M. Biological evaluation of hepatitis C virus helicase inhibitors. Bioorg. Med. Chem. Lett. 11:2001;1647-1650.
63. Poole T.L., Wang C., Popp R.A., Potgieter L.N., Siddiqui A., Collett M.S. Pestivirus translation initiation occurs by internal ribosome entry. Virology. 206:1995;750-754.
64. Porter D.J., Preugschat F. Strand-separating activity of hepatitis C virus helicase in the absence of ATP. Biochemistry. 39:2000;5166-5173.
65. Poynard T., Marcellin P., Lee S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeucem S., Trepo C., Albrecht J. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 352:1998;1426-1432.
66. Preugschat F., Averett D., Clarke B., Porter D. A steady-state and presteady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain. J. Biol. Chem. 271:1996;24449-24457.
67. Pryor M.J., Gualano R.C., Lin A.D., Davidson A.D., Wright P.J. Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins. J. Gen. Virol. 79:1998;2631-2639.
68. Quin J.W. Interferon therapy for acute hepatitis C viral infection - a review by meta-analysis. Aust. NZ J. Med. 27:1997;611-617.
69. Rice M.C. Flaviviridae: the viruses and their replication. Knipe D.M., Howley P.M., third ed. Fields Virology. 1:1996;931-960 Lippincott-Raven Publishers, Philadelphia, PA.
70. Shoji I., Suzuki T., Sato M., Aizaki H., Chiba T., Matsuura Y., Miyamura T. Internal processing of hepatitis C virus NS3 protein. Virology. 254:1999;315-323.
71. Spector F.C., Liang L., Giordano H., Sivaraja M., Petersen M.P. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J. Virol. 72:1998;6979-6987.
72. Suzich J., Tamura J., Palmer-Hill F., Warrener P., Grakoui A., Rice M.C., Feinstone S., Collett M. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J. Virol. 67:1993;6152-6158.
73. Taber L.H., Knight V., Gilbert B.E., McClung H.W., Wilson Z.S., Norton H.J., Thurson J.M., Gordon W.H., Atmar R.L., Schlaudt W.R. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics. 72:1983;613-618.
74. Tai C.-L., Chi W.-K., Chen D.-S., Hwang L.-H. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J. Virol. 70:1996;8477-8484.
75. Tamura J.K., Warrener P., Collett M.S. RNA-stimulated NTPase activity associated with the p80 protein of the pestivirus bovine viral diarrhea virus. Virology. 193:1993;1-10.
76. Tsukiyama-Kohara K., Iizuka N., Kohara M., Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J. Virol. 66:1992;1476-1483.
77. Walker J.E., Saraste M., Runswick M.J., Gay N.J. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J. 1:1982;945-951.
78. Warrener P., Collett M.S. Pestivirus NS3 (p80) protein possesses RNA helicase activity. J. Virol. 69:1995;1720-1726.
79. Wassarman D.A., Steitz J.A. RNA splicing. Alive with DEAD proteins. Nature. 349:1991;463-464.
80. Westeway E.G. Flavivirus replication strategy. Adv. Virus Res. 33:1987;45-90.
81. Wu Q., Bounaud P.Y., Kuduk S., Yang C.P., Ojima I., Horwitz S., Orr G. Identification of the domains of photoincorporation of the 3′- and 7-benzophenone analogues of taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein. Biochemistry. 37:1998;11272-11279.
82. Yao N., Hesson T., Cable M., Hong Z., Kwong A., Le H., Weber P. Structure of the hepatitis C virus RNA helicase domain. Nature Struc. Biol. 4:1997;463-467.
83. Zhong W., Ingravallo P., Wright-Minogue J., Skelton A., Uss A.S., Chase R., Yao N., Lau Y.N., Hong Z. Nucleoside triphosphatase and RNA helicase activities associated with GB virus B nonstructural protein 3. Virology. 261:1999;216-226.
84. Zhu K., Henning D., Iwakuma T., Valdez B.C., Busch H. Adriamycin inhibits human RH II/Gu RNA helicase activity by binding to its substrate. Biochem. Biophys. Res. Commun. 266:1999;361-365.
85. Zoulim F., Haem J., Ahmed S.S., Chossegros P., Habersetzer F., Chewallier M., Bailly F., Trepo C. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J. Viral. Hepat. 5:1998;193-198.